Genetic Testing in Detection of Late-Onset Hearing Loss (SoundGene)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00511381|
Recruitment Status : Completed
First Posted : August 3, 2007
Last Update Posted : March 1, 2012
|Condition or disease||Intervention/treatment|
|Hearing Loss Late-Onset Hearing Loss Deafness||Genetic: No intervention|
Two major limitations of existing audiometric newborn hearing screening programs are their inability to detect forms of deafness that are not expressed at birth and the low compliance with obtaining recommended audiologic confirmation and/or follow-up. Molecular genetic tests on blood spots from all newborns will identify those at risk for the most frequent causes of late-onset hearing loss and to add these infants to the group who should receive continued audiologic monitoring.
The specific aims of this project are to:
- Demonstrate the utility of detecting four potentially important causes of delayed onset hearing loss by molecular tests at birth, which may be missed by current audiometric screening tests.
- Document the frequency, clinical and genetic characteristics of hearing loss associated with each condition.
Dried blood spots (DBS) on filter paper will be obtained and be used for this project with parental informed consent from 6,000 newborn infants at approximately 25 hospitals. Pediatrix Screening, a subsidiary of Pediatrix Medical Group with long experience in high throughput neonatal testing, will perform genetic testing on the samples. The four genetic and environmental forms of deafness to be studied include:
Prenatal/congenital cytomegalovirus (CMV) infection
-Detecting the presence of CMV viral DNA in dried blood spots.
Connexin Deafness - GJB2 and GJB6 mutations
- Cx26 35delG, Cx26 235delC, Cx26 167delT, Cx26 M34T, and Cx30 large deletion.(Under sublicense with Athena Diagnostics, Inc: United States Patent Numbers: 5,998,147 and 6,485,908 and patents pending)
Pendred Syndrome - SLC26A mutations
- L236P, 1001 +1G>A, T416P, E384G
- Mitochondrial Mutations - T961C, T961G, G951A, 961 delT+C(n)Ins, G7444A, A7445G, A7445C.
|Study Type :||Observational|
|Actual Enrollment :||3681 participants|
|Official Title:||Utility of Genetic Testing in Detection of Late-Onset Hearing Loss|
|Study Start Date :||October 2007|
|Actual Primary Completion Date :||September 2009|
|Actual Study Completion Date :||September 2011|
Genetic: No intervention
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00511381
|United States, Kansas|
|Topeka, Kansas, United States, 66604|
|United States, Ohio|
|Miami Valley Hospital|
|Dayton, Ohio, United States, 45409|
|United States, Oklahoma|
|Integris Baptist Medical Center|
|Oklahoma City, Oklahoma, United States, 73112|
|Principal Investigator:||Gail Lim, ARNP||Mednax Center for Research, Education, Quality and Safety|
|Study Chair:||Zhili Lin, MD, PhD||Pediatrix Screening|
|Study Chair:||Reese H Clark, MD||Mednax Center for Research, Education, Quality and Safety|